

# Sialorrhea: Considerations and Management

**Elton Lambert, MD** Assistant Professor Texas Children's Hospital Baylor College of Medicine

# Outline

Texas Children's Hospital<sup>®</sup>

> Baylor <sup>College of</sup> Medicine

- Basics of Salivary Flow and Sialorrhea
- Social and Medical Implications of Sialorrhea
- Pharmacologic Agents
- Botox
- Surgical Interventions

#### **Basics of Sialorrhea**

- · Unintentional loss of saliva from the mouth
  - Anterior spilling from the mouth that is clearly visible
  - Posterior spilling posteriorly creating an aspiration risk
- Generally not due to excessive salivary secretion
  - · Dysfunction of the oral phase of swallowing
  - Deficient lip closure
  - Disorganized tongue movement
  - Reduced frequency of swallowing


## **Effects of Sialorrhea**

- Social rejection
- Constant damp and soiled clothing
- Unpleasant odor
- Irritated facial skin
- · Oral and perioral infections

- · Oral and perioral infections
- Dehydration
- Decreased masticatory function
- Damage to books and communication devices
- Aspiration

Interventions for drooling in children with cerebral palsy. Walshe M, Smith M, Pennington L. Cochrane Database Syst Rev 2012 Nov 14:11

### **Basics of Sialorrhea**



# **Pharmacologic Agents**

#### Muscarinic Anticholinergic Agents

- Glycopyrrolate
- Scopolamine
- Benztropine
- Atropine


### Side Effects

- Xerostomia
- Urinary retention
- Constipation
- Drowsiness
- Behavioral changes

#### **Botulinum Toxin**

- Blocks presynaptic release of acetylcholine
- Reduces amount of saliva
- Generally 1U/Kg per gland
- Direct injection versus ultrasound guided






# **Botulinum Toxin (Botox)**

Reference	Weight (%)	SMD (95% CI)	
Ondo (2004) <sup>14</sup>	11.5	-1.42 (-2.56 to -0.29)	<b>⊢</b> −•−−1
Reid (2008) <sup>15</sup>	17.7	-1.96 (-2.67 to -1.26)	<b>⊢</b> •–1
Lin (2008) <sup>16</sup>	9.4	-1.66 (-2.99 to -0.33)	<b>⊢</b> →→
Alrefai (2009) <sup>17</sup>	12.7	-0.79 (-1.83 to 0.24)	<b>⊢</b> •-+
Jackson (2009) <sup>18</sup>	13.5	-0.85 (-1.83 to 0.12)	<b>⊢</b> •
Lagalla (2009) <sup>19</sup>	16.2	-1.85 (-2.64 to -1.05)	<b>⊢</b> •−i
Steinlechner (2009) <sup>20</sup>	8.6	-0.51 (-1.94 to 0.92)	<b>⊢</b> • <u>+</u>
Basciani (2011) <sup>21</sup>	10.5	-3.03 (-4.25 to -1.80)	<b>⊢</b> •−−1
Overall	100.0	-1.54 (-2.05 to -1.04)	⊢⊶
		4	50 -45 -40 -35 -50 -25 -20 -13 -10 -45 -00 -63 -10 -12 Standardized Mean Difference (SMD)

Complication	Number of Events (%; N = 181)	
Head and neck complications		
Increased saliva thickness	7 (3.9)	
Dysphagia	6 (3.3)	
Xerostomia (dry mouth)	6 (3.3)	
Increased drooling (transient)	2 (1.1)	
Bruxism	I (0.6)	
Burnt taste	I (0.6)	
Chin drop	I (0.6)	
Loose jaw	I (0.6)	
Neck pain	I (0.6)	
Speech problems	I (0.6)	
Other (systemic) complications		
Pneumonia	4 (2.2)	
Generalized weakness	2 (1.1)	
Percutaneous endoscopic	2 (1.1)	
gastrostomy tube placement		
Shortness of breath	2 (1.1)	
Worsened gait	2 (1.1)	
Baclofen pump	I (0.6)	
Cardiac arrest	I (0.6)	
Chest infection	I (0.6)	
Deep venous thrombosis	I (0.6)	
Diarrhea	I (0.6)	
Nausea/emesis	I (0.6)	
Seizure (new onset)	1 (0.6)	

Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013 Feb;148(2):191-6.

## **Tympanic Neurectomy**



## Salivary Gland Surgery

- Submandibular Duct Rerouting
- · Parotid Gland Duct Rerouting
- Submandibular Gland Duct Ligation
- Parotid Gland Duct Ligation
- Submandibular Gland Excision
- Parotidectomy

Table 2. Results Summary

Characteristic	No. of Studies 59	Subjective Success Rate (95% Confidence Interval), % 81.6 (77.5-85.7)
Overall		
Mean follow-up duration		
≥1 year	42	83.9 (78.6-89.1)
<1 year	17	76.6 (68.9-84.4)
Surgical procedure		
BSM duct rerouting	21	84.4 (77.7-91.1)
BSMG excision and bilateral parotid duct rerouting	8	87.8 (80.5-95.1)
BSMG duct rerouting and BSLG excision	8	71.5 (63.6-79.4)
BSMG excision and bilateral parotid duct ligation	9	85.2 (78.6-91.7)
4-Duct ligation	4	64.1 (27.6-100)

Abbreviations: BSLG, bilateral sublingual gland; BSM, bilateral submandibular; BSMG, bilateral submandibular gland.

Surgical management of drooling: a meta-analysis. Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):924-31 Reed J1, Mans CK, Brietzke SE

#### Schema in the Management of Drooling in Children

- Review of posture and positioning
- Oral awareness and oral motor skills training (possibly also with an oral stimulation device)
- Orthodontic treatment
- Pharmacotherapy
- Botulinum toxin
- Surgery

Little SA, Kubba H, Hussain SS.An evidence-based approach to the child who drools saliva.Clin Otolaryngol. 2009 Jun;34(3):236-9.

## Conclusion

- Drooling or sialorrhea is unintentional loss of saliva from the oral cavity
- There are many social and medical implications that can arise from sialorrhea/drooling
- Pharmacologic agents can have a high number of negative side effects
- Botox injection serves as a localized pharmacologic agent for drooling
- · Salivary gland surgery can be effective in many patients

#### References

- Interventions for drooling in children with cerebral palsy. Walshe M, Smith M, Pennington L. Cochrane Database Syst Rev. 2012 Nov 14;11.
- Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis.Otolaryngol Head Neck Surg. 2013 Feb;148(2):191-6.
- Surgical management of drooling: a meta-analysis.Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):924-31. Reed J1, Mans CK, Brietzke SE.
- Little SA, Kubba H, Hussain SS.An evidence-based approach to the child who drools saliva.Clin Otolaryngol. 2009 Jun;34(3):236-9.